Researchers tested the drug, not yet on the market, in mouse models of Lyme disease at seven-day, 14-day, and 21-day intervals and found that it eliminated the infection. For the first time, azlocillin also proved effective in killing drug-tolerant forms of B. burgdorferi in lab dishes, indicating that it may work as a therapy for lingering symptoms of Lyme disease.

Researchers plan to conduct a clinical trial.

One day... Maybe.